StemCell Therapy

Denali Therapeutics Inc (DNLI) is near the top in its industry group according to InvestorsObserver. DNLI gets an overall rating of 65. That means it scores higher than 65 percent of stocks. Denali Therapeutics Inc gets a 84 rank in the Biotechnology industry. Biotechnology is number 31 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 65 means the stock is more attractive than 65 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Denali Therapeutics Inc (DNLI) stock is trading at $36.01 as of 3:36 PM on Monday, Sep 14, a rise of $4.02, or 12.57% from the previous closing price of $31.99. The stock has traded between $31.75 and $36.12 so far today. Volume today is high. So far 1,773,161 shares have traded compared to average volume of 842,601 shares.

Click Here to get the full Stock Score Report on Denali Therapeutics Inc (DNLI) Stock.

Link:
Is Denali Therapeutics Inc (DNLI) a Winner in the Biotechnology Industry? - InvestorsObserver

This entry was posted on September 15, 2020 at 11:14 am and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |